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1. INTRODUCTION  
The history of organ transplantation, and of transferring organs and body parts from one 
man to another, or from an animal to a human being date back thousands of years. One 
of the earliest and perhaps most well-known story is about Saints Cosmas and Damian, 
who replaced a severed leg of a verger with a leg from a dead man in the 2nd Century. 
The story has been portrayed in many paintings; in fact the two are still respected patron 
saints of today's physicians and surgeons. 
In the history of kidney transplantation in the 20th century, a researcher and physician 
from Pecs played a role as well. Imre Ullmann (Emerich Ullmann) performed 
successful kidney transplants in a number of animal experiments, but his attempt in 
1902, in which he transplanted a goat kidney into a woman, ended unsuccessfully. 
Successful and safe kidney transplantation only began in the 1960s and 1970s. The first 
successful kidney transplant is attributed to Murray et al., who carried out a transplant 
between identical twin siblings on December 23, 1954 in Boston. In order for organ 
transplantation to further progress the development of detailed vascular suture 
techniques and experimental methods of kidney removal and implantation were needed. 
A solution had to be found for immunological questions with the legal and ethical 
background of the intervention being ensured as well. 
The development of immunosuppression further boosted the progression of 
transplantation. Initially total body irradiation and high-dose steroid monotherapy were 
applied with supplementary azathioprine from 1962; however the real breakthrough was 
brought on by the clinical introduction of cyclosporine. 
In this day and age surgical techniques, immunosuppression as well as additional tests 
leading to a successful surgery (i.e. immunological typing) have evolved to such a level, 
where long term success of the transplantation is not primarily determined by these 
factors. Leading causes of post-transplant complications are cardiovascular diseases, 
infections and cancer. It is thus clear that the improvement of long-term results is based 
on the prevention of these diseases. 
Thanks to advanced immunosuppression, it is possible to improve patient and graft 
survival compared to what we achieve at present. However, the average age of patients 
that are operated on keeps growing, thus the long-term survival is expected decline in 
the future. The paradoxical dichotomy between demand and reality will determine the 
future of organ transplantation greatly. 
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2.  OBJECTIVES  
In my research I examined the leading cardiovascular complications after kidney 
transplantations and simultaneous pancreas and kidney transplantations, the frequency 
and preventive opportunities of mortality.  
 
1. I provide an overview of the complications and long-term results of kidney and 
simultaneous pancreas-kidney transplantation. My objective was to assess the risk 
factors among the patients of our clinic, and to compare them with the average 
population values. 
 
2. I review the possibilities of platelet aggregation inhibition, which is one of the 
cornerstones of cardiovascular prevention. I introduce tests for assessing the 
effectiveness of the therapy, with special emphasis on optical aggregometry which 
was used in my own research as well. The phenomenon of resistance against platelet 
aggregation inhibitors is well-known, so in my research I assess resistance to acetyl-
salicylic acid (ASA) and clopidogrel among transplant patients. I compare the results 
to the results of a group of patients with a history of cardiovascular diseases. 
 
3. On top of general factors resulting in resistance known from scientific literature, I 
analyse the causes of the development of resistance using special variables of our 
patient material. 
 
4. According to the literary references, in case of the emergence of resistance we change 
preventive treatment, and then check its effectiveness with a re-test. 
 
5.  I compare cardiovascular mortality and complications from before the beginning of 
the research to data found in scientific literature, and to the time period lasting from 
the first aggregometric measurements to now. The results are compared to a control 
group’s data, which has previous positive cardiovascular history. 
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3.  ABOUT KIDNEY AND SIMULTANEOUS PANCREAS-KIDNEY 
TRANSPLANTATIONS AND COMPLICATIONS  
 
3.1. The long-term complications of kidney transplantation 
A number of factors play a role in the progression of chronic kidney failure: diabetes 
mellitus, hypertension, smoking and dyslipidaemia. Despite the fact that kidney 
replacement therapy (haemodialysis, peritoneal dialysis) keeps developing day by day, 
there is evidence that in terms of patients’ quality of life and survival, and also cost-
effectiveness, kidney transplantation is the best treatment. 
Based on data of a 17-year retrospective study, 1, 5 and 10 year survival rates were 
significantly higher among transplant patients, compared to those, who were undergoing 
haemodialysis: 95.2, 88.0 and 78.8% vs. 90.6, 62.7 and 39.8%. 
Because of the well-proven surgical technique of kidney transplantation, today we can 
rarely expect complications to occur. The vast majority of complications after surgery 
can be attributed to diseases from before the operation or flare ups of immune reactions 
after the transplantation, and immunosuppression. The long-term results are basically 
determined by the origin of the organ donor (cadaver vs living donors), surgery, 
complications developed during the postoperative stage, and aftercare. 
It would seem obvious that most commonly occurring side effects of 
immunosuppressive therapy after transplantation are infections and tumours. But this 
concept is not correct. The study of Matas et al., which examined 2,202 renal transplant 
recipients for more than 10 years, revealed the following main causes of death: 
- Cardiovascular causes: 35% and 38% (Living and cadaver donors) 
- Cancer: 29% and 22% 
- Infection: 13% and 9%. 
 
3.1.1. Cardiovascular complications 
Cardiovascular risk factors in general 
The main risk factors such as smoking, diabetes mellitus, hypertension, dyslipidaemia, 
obesity, and certain non-modifiable factors such as age, sex, genetic predisposition play 
a significant role in this patient group too. 
Specific and general cardiovascular risk factors of patients suffering from kidney 
disease and having undergone kidney transplantation are listed in Table 1 based on 
medical literature. 
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hypertension (donor and recipient) hyperuricemia 
diabetes mellitus calcium-phosphorus homeostasis disorder 
hyperlipidaemia inflammatory diseases 
obesity hyperhomocysteinemia 
increasing age (donor and recipient) increased trombopoesis 
sex poliglobulia 
genetic predisposition increased blood clotting 
microalbuminuria reduced fibrinolytic activity 
uraemia increased haemoglobin levels 
anti-platelet therapy is less effective increased blood viscosity 
graft artery stenosis higher haematocrit 
immunosuppression acute rejection 
high CRP levels chronic allograft nephropathy 
cytomegalovirus infection metabolic syndrome 
Table 1: Cardiovascular risk factors 
 
3.2. The characteristics of simultaneous pancreas-kidney transplantation  
Type 1 diabetes mellitus is one of the most common chronic diseases among children 
that have a key role in determining life expectancy. Appropriate treatment of the disease 
is especially important, otherwise serious complications can occur: microvascular 
damage, such as retinopathy, neuropathy and nephropathy, and macrovascular damage 
which affects the cerebrovascular system, peripheral vascular and coronary system as 
well. 
The simultaneous pancreas and kidney transplantation is indicated in patients, with type 
1 diabetes mellitus and uraemia or pre-uraemia (serum creatinine is twice as much as 
the upper limit of the normal ranges). The results of combined transplantation are 
significantly better than that of dialysis, or kidney transplantation alone. 
It is important to take into account post-operative complications, since with their 
possible prevention and treatment results can be further improved. Rogers et al analysed 
the results of 156 transplants focusing on two main things: what were the causes of 
pancreatic and renal graft loss. In case of pancreatic graft loss most were due to early 
and late thrombosis, but organs were lost because of infections and rejection as well. 
The leading cause of graft loss after kidney transplantation was chronic allograft 
nephropathy but infections, graft thrombosis and acute rejection played an important 
role as well.  
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A study by Sollinger et al of 1000 post-transplant patients found that 5, 10 and 20 year 
survival rates were 89, 80, and 58% respectively. 
Main causes of mortality after simultaneous transplantation in patients with functioning 
grafts are cardiovascular diseases. The incidence of cerebrovascular, cardiovascular and 
peripheral arterial diseases within the first five years after transplantation  are 33, 41 and 
41% respectively based on a study of a group of patients by Biesenbach. These results 
further deteriorated (41, 50, 50% respectively) after a period of ten years.   
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4.  ANALYSIS OF OUR PATIENT POOL IN LIGHT OF RISK FACTORS  
 
4.1. Objectives 
The assessment of causes of mortality in patients that underwent transplantation. The 
assessment of cardiovascular risk factors in patients that underwent transplantation after 
the commencement of the study. The analysis of data pertaining to kidney or 
simultaneous kidney-pancreas transplant recipients, and the assessment of 
cardiovascular risk factors. 
4.2. Patient pool and methods 
Between 3 September 1993 and 28 February 2009 based on our electronic database, the 
assessment of mortality causes of 586 patients was carried out who underwent 
transplantation in our facility.  
After which all patients that received organ transplants and some form of antiplatelet 
therapy after the surgery between March 2009 and December 2013 were added to the 
trial in the Department of Surgery of University of Pecs. Their date are summarised in 
Table 2.  
Kidney transplant recipients 
Total 254 
Man 154 
Woman 100 
Average age 53,87±13,0 years 
Simultaneous pancreas-kidney transplant recipients 
Total 32 
Man 22 
Woman 10 
Average age 47,35±8,57 years 
Table 2: Data of study population 
In order to assess cardiovascular risk factors the following parameters were determined 
by the Department of Laboratory Medicine University of Pecs, renal function, fasting 
glucose, HbA1c, total cholesterol, triglycerides, haemoglobin concentration, 
haematocrit, platelet count, urinalysis. 
At our transplant outpatient clinic blood pressure, weight and height were measured, 
from BMI values were calculated. The proportion of smokers was determined based on 
personal interviews. We kept track of their medication and comorbidities on their 
individual registration sheet. Their data were compared to laboratory reference ranges 
and average values of the Hungarian population. 
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4.3. Results 
In a period stretching from 1993 to 2009 the death of patients having undergone organ 
transplantation could be traced back to cardiovascular diseases in most cases. They were 
followed by infections and malignant diseases. 
Mortality cause Number of patients 
Cardiovascular disease 65 (11.09%) 
Infection 36 (6.14%) 
Cancer 12 (2.04%) 
Other causes (accident, suicide, surgical 
complications, etc.). 
9 (1.53%) 
Table 3: Causes of mortality in transplant patients (1993-2009) 
The data of patients with renal transplant and combined surgeries are summarised 
separately in the table below. (Table 4 and 5) 
 
 Kidney SPK 
Average 
population 
Diabetes mellitus (%) 6.3 N.A. 7.47 
BMI (kg / m2) 26.37 28.24 - 
Smoking (%) 7.48 3.13 19 
Increased triglycerides (%) 54.33 28.13 40 
Increased cholesterol levels 
(%) 
46.46 28.13 66 
Antilipid treatment (%) 28.35 18.75 ~6 
Table 4: The incidence of cardiovascular risk factors in transplant patients compared to 
the general population  
 
 Kidney SPK 
Local normal 
lab values 
blood glucose level (mmol/L) 6.07 5.88 3.9-5.6 
platelet count 239.28 283.28 150-300 
haematocrit 0.385 0.394 0.37-0.51 
haemoglobin 124.91 125.59 120-180 
Table 5: The incidence of cardiovascular risk factors in transplant patients compared to 
normal ranges of the local laboratory 
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4.4. Discussion 
According to an extensive survey conducted in 2008 the incidence of type I diabetes 
mellitus was 7.47% in the Hungarian population between the ages of 20 and 69. Even 
though almost a quarter of patients that underwent kidney transplantation develop 
diabetes, within our test group the incidence of diabetes requiring treatment was only 
6.3%. It is evident that patients undergoing simultaneous transplantation have a 100% 
incidence of diabetes since the indication of the procedure is having type 1 diabetes. 
Mean blood glucose values in renal, and simultaneous pancreas- kidney transplant 
recipients were 6.07 ±1.33 and 5.88±1.89 mmol/L respectively. According to 
recommendations fasting glucose should be kept below 6.0 mmol/L and postprandial 
values below 7.5 mmol/L. In both patient groups mean values were kept within 
recommended ranges. Physiological insulin secretion and long lasting normal insulin 
levels, which are the real advantages of simultaneous pancreas- kidney transplantation, 
are best reflected by HbA1c values, which on average were 5.57±0.86%. In diabetic 
patients a target value below 7.0% is recommended according to guidelines.  
40% of the Hungarian population is overweight and 20% exceeds a BMI of 30kg/m
2
 
thus they fall under the ’obese’ category. For patients suffering from chronic kidney  
diseases a value below 25kg/m
2
 should be targeted whilst patients without 
cardiovascular symptomes but at great risk thereof should stay below 27kg/m
2
. Our 
kidney transplant patients’ BMI averages 26.37kg/m
2
 which falls between the two 
aforementioned values, and our simultaneous pancreas- kidney transplant patient 
average 28.24kg/m
2
 which isn’t a significant deviation (p>0.5) from the reference value.  
 
Based on a survey conducted in 2013, 19% of the Hungarian population smokes on a 
daily basis. According to the interviews with our patients only 7.48  and 3.13% of them 
smoke. 
 
According to a 9000 patient study, 66% of the adult population have cholesterol levels 
above the upper limit of the normal range which is 5.2 mmol/L.  25% of this group has 
serum cholesterol levels exceeding 6.5 and 7-8% above 7.8 mmol/L. Mean serum 
cholesterol was 5.7 mmol/L. Trigliceride levels were above the recommended 2.3 
mmol/L(it has since changed)  limit in 18% of the population. Recently however the 
reference value has dropped to 1.7 mmol/L thus the prevalence of trigliceridemia has 
reached around 40%.  Hypercholesterolemia (>5.2 mmol/L) was found in 46.46%  and 
28.13% of our patients, while hypertrigliceridemia (1.7 mmol/L) was found in 54.33% 
and 28.13%. 28.35 and 18.75% of our patients recieve antilipid therapy. Comparing 
these results with our own we can conclude that in Hungary about 6% of the population 
is on lipid lowering medications (2/3 of which are statins), but it is estimated that every 
5th person needs therapy. It is clear that lipid metabolic disorders are common amongst 
our patients but in their case it is also more often recognised and appropriately treated as 
opposed to the general population.  
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Thrombotic events occure more often in patients with higher hematocrit, hemoglobin 
levels and elevated platelet count. All three parameters were found to be in normal 
range in both patients groups. The frequent incidence of high blood pressure is not 
considered significant neither was diabetes in kidney transplant recipients since most 
patients alredy suffer from these conditions when they first  see a transplant surgeon and 
they rarely cease after transplantation.  
All in all we can conclude that according to our assessment apart from trigiceridaemia 
in kidney transplant recipients no conventional risk factor was found which is clearly 
linked to the increased cardiovascular mortality of transplanted population, and the 
increased mortality compared to the general population. We assume that the vascular 
damage in the pre-transplant uremic period plays an important role in the process and so 
does the post transplant immunosupression. 
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5.  PLATELET AGGREGATION INHIBITION AND DEVELOPMENT OF 
RESISTANCE  
 
5.1. Introduction 
Cardiovascular prevention after kidney transplantation is dealt with in detail in the 2009 
KDIGO guidelines. They recommend a daily dose of 65-100 mg acetylsalicylic acid if 
there are no contraindications against it as part of the prevention. 
This guideline also refers to a retrospective study where low doses of ASA significantly 
improved graft survival. Grotz et al found that both graft survival and function 
improved with ASA therapy in kidney transplant patients.  
5.2. Objectives 
In the following section the possibilities of modern platelet aggregation inhibition and 
also methods capable of determining effectiveness are summarised. After which the 
definition of ASA and clopidogrel resistance are dealt with. In this part of the study 
ASA and clopidogrel resistance are assessed using optical aggregometry in our patient 
group. Data obtained were compared to data found in other scientific literature. 
I tried to find answers to the following questions: 
- what is the incidence of resistance after transplantation 
 - and compared to a control group 
 - and does it contribute to the cardiovascular risk explained in the                                         
previous chapter 
5.3. Platelet aggregation inhibition today 
The discovery of the coagulation cascade process dates back to the 1960s, when Davie, 
Ratnoff and Macfarlane through their experiments found the role of interacting factors 
and enzymes. Platelets have a key role in the coagulation process, through their 
adhesion, activation and aggregation as part of the cascade thrombi develop. This 
process, associated to bleeding, does not only occur with injuries. Platelet activation 
primarily occurs when normal, linear blood flow changes to turbulent (e.g. sclerotic, 
narrowed vasculature, valves) and after the erosion and rupture of atherosclerotic 
plaques. The clots formed this way may cause ischemic damage (e.g.: stroke, acute 
myocardial infarction). 
We intervene in a number of ways to prevent aggregation, with the available therapeutic 
possibilities (acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb-IIIa 
antagonists). 
5.4. Examination of platelet functions, monitoring the efficiency of aggregation 
inhibition 
There is many therapeutic interventions and methods used to assess the effectiveness of 
therapy (bleeding time, platelet function analyser, flow cytometry, urine thromboxane 
test, tromboelastometry / graphy, Verify Now). The gold standard method at the present 
is platelet aggregometry, which was used in my research as well. 
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5.5. Acetyl salicylic acid and clopidogrel resistance 
Resistance to platelet aggregation inhibitors became the centre of attention of clinical 
trials in the early 2000s.  
There are also several positions regarding the definition:  
- The laboratory definition of acetylsalicylic acid and clopidogrel resistance is when 
different platelet function tests show that aggregation inhibition does not correspond 
with our expectations and the frequency of cardiovascular events is also greater. 
- A clinical definition is much simpler: resistance can be established retrospectively if a 
thrombotic event occurs despite the use of anti-aggregation treatment. 
- Recently more and more publications use the concept of residual platelet reactivity 
(high on-treatment platelet reactivity). Objective criteria are necessary for definition. 
The goal is to numerically determine the activity of target receptors before and after 
treatment. The usability of the term presents a problem, since the device used for the 
measurement is still not standardised and neither is the time thereof.  
The degree of resistance to both ASA and clopidogrel was the subject of several studies. 
In most studies, different methods and therapeutic regimens with different drug doses 
used are compared, however, in both cases drug resistance can be as much as 40-50%. 
5.6. Patients and methods 
Patients’ data are summarized in Table 2. 
214 of the 254 renal transplant patients was given a daily dose of 100 mg acetylsalicylic 
acid while 40 received for other cardiovascular indications 75 mg clopidogrel daily. All 
the 32 simultaneous pancreas- kidney transplant recipients were given ASA. Patients 
taking either products were required to do so for a minimum of 3 months. 
A blood sample needed for measuring platelet aggregation was drawn from the cubital 
vein in the morning on empty stomach into 3.8% Na citrate Vacutainer tubes. 
Antiplatelet drugs were taken a day before blood collection. The test was performed at 
1st Department of Internal Medicine, University of Pecs. Following multiple courses of 
centrifugation first platelet rich (PRP) then platelet poor plasma (PPP) was obtained; 
platelet aggregation was induced with ADP (concentration: 5mM and 10 mM), and with 
epinephrine (10mM). The test was performed using a Carat TX-4 platelet aggregometer 
(Carat Diagnosztika Kft., Budapest) which works on the principle of turbidimetry, and 
calculates the degree of aggregation relying on the difference between PPP-PRP optical 
densities. We use epinephrine to examine the effect of ASA and ADP to assess 
clopidogrel effectivity. A decrease in maximum aggregation is considered to be the 
consequence of therapy, if it is not in target range of the normal population 
(mean±2SD), otherwise therapy is deemed ineffective. ASA treatment is considered 
effective as long as the degree of induced aggregation is not over 40%, or 50% with 
clopidogrel. 
In order to get even more accurate results treatment was considered ineffective if two 
consecutive tests also confirmed inappropriate aggregation inhibition. 
Comparison with resistance data of other patient groups was carried out using two 
sample t test with the help of IBM SPSS software (IBM Corporation, Armonk, New 
York, United States), Version 21.0. 
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5.7. Results 
Renal transplant recipients 254  
    ASA resistant 86 40.18% 
    Not resistant ASA  128 59.81 
    Clopidogrel resistant 24 60% 
    Not resistant to clopidogrel  16 40% 
Simultaneous pancreas- kidney 
transplant recipients 
32  
    ASA resistant 13 40,63% 
    Not resistant to ASA  19 59.37% 
Total number of transplant 
recipients 
286  
    Resistant 123 43% 
    Not resistant 163 57% 
Table 6: transplant patients acetylsalicylic acid and clopidogrel resistance 
 
Based on the overall results of the transplanted population we examined we see that in 
43% (123 patients) therapy was ineffective. 
Comparing our patients’ resistance values with data found in scientific literature it is 
evident that the incidence of resistance after transplantation is significantly higher 
(p<0.05) than in other examined patient groups. 
 
5.8. Discussion 
High resistance measured in our patients may contribute to the more frequent incidence 
of cardiovascular complications, and can be a cause of increased cardiovascular 
mortality. That is why it is important to explore the underlying mechanisms of the 
phenomenon and, if resistance is present convert to a different drug. 
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6.  POSSIBLE CAUSES OF ACETYLSALICYLIC ACID RESISTANCE 
AND CLOPIDOGREL RESISTANCE  
 
6.1. Introduction 
Because of the high prevalence of resistance to platelet aggregation inhibitors many 
research groups are looking for the causes of the phenomenon. When designing my own 
research one of my goals was to find a factor that may explain the increased resistance 
among transplant patients. First, I collected available date from scientific literature, and 
I completed them with the analysis of certain factors only typical for our patient group 
(e.g. immunosuppressive drugs). 
6.2. Patients and methods 
254 patients were selected into the study that was previously enrolled into our 
aggregometric examination, furthermore another 32 patients that underwent 
simultaneous pancreas- kidney transplantation (Table 2). 
The following parameters were determined from the serum of the subjects in the 
Department of Laboratory Medicine, University of Pécs: creatinine, glucose, 
cholesterol, triglycerides, haemoglobin concentration, haematocrit, and platelet count. 
In our transplant outpatient clinic patients’ weight, height and BMI (calculated from the 
other two parameters) were measured. Smokers were identified during personal 
interviews, and so were medicines used in therapy that may have affected resistance 
according to literature. The frequency of chronic allograft nephropathy and steroid 
resistant acute rejection were also assessed.  
A total of 24 variables were analysed which are summarized in Table 7. 
The statistical analysis of the available data was carried out using the 21.0 version of the 
IBM SPSS software (IBM Corporation, Armonk, New York, United States) with 
logistic regression analysis. 
 
age mycophenolate mofetil ACE inhibitors 
Se creatinine level methylprednisolone CAN 
diabetes mellitus tacrolimus SRAR 
type of transplantation cyclosporine platelet count 
BMI mycophenolic acid haematocrit 
Se triglyceride level everolimus Se glucose 
Se cholesterol level sirolimus haemoglobin 
anti-lipid therapy Calcium channel blockers smoking 
ARB   
Table 7: We investigated the possible factors associated with resistance 
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6.3. Results 
Statistically significant correlation could only be detected in the group taking ASA. In 
patients receiving anti-lipid therapy (statin therapy) resistance occurred at lower rates. 
In patients taking cyclosporine containing products resistance occurred at a significantly 
higher rate as opposed to those not taking it (Table 8.) In the clopidogrel treatment 
group none of the examined factors were found to affect resistance significantly. 
 
 
 beta coefficient p value OR 
95% C.I. for OR 
lower upper 
BMI -,002 ,980 ,998 ,865 1,152 
hematocrit -,006 ,965 ,994 ,772 1,280 
platelet count ,000 ,906 1,000 ,995 1,005 
type of transplant -,251 ,774 ,778 ,140 4,320 
methylprednisolone -,174 ,616 ,840 ,426 1,658 
CAN ,522 ,562 1,685 ,289 9,813 
ARB -,311 ,417 ,733 ,346 1,552 
age ,010 ,445 1,010 ,985 1,036 
tacrolimus ,424 ,485 1,529 ,465 5,031 
everolimus ,472 ,418 1,603 ,512 5,022 
Se triglyceride level ,301 ,371 1,351 ,699 2,609 
diabetes mellitus -,742 ,379 ,476 ,091 2,485 
Se cholesterol level -,273 ,393 ,761 ,406 1,425 
Se glucose ,120 ,362 1,128 ,871 1,461 
smoking ,592 ,327 1,807 ,553 5,906 
hemoglobine level -,011 ,272 ,990 ,971 1,008 
SRAR -1,172 ,232 ,310 ,045 2,115 
mycophenolic acid ,877 ,220 2,403 ,592 9,760 
mycophenolate 
mofetil 
,198 ,546 1,219 ,641 2,316 
ACE inhibitors ,436 ,174 1,547 ,824 2,903 
sirolimus ,645 ,168 1,907 ,761 4,776 
Calcium channel 
blockers 
-,527 ,108 ,590 ,310 1,123 
Se creatinine level -,004 ,073 ,996 ,993 ,999 
anti-lipid therapy ,682 ,050 1,979 ,990 3,955 
cyclosporine -1,042 ,001 ,353 ,192 ,649 
 
Table 8: Results of multiple variable logistic regression of those receiving ASA therapy 
(BMI: body mass index, CAN: chronic allograft nephropathy, ARB: angiotensin 
receptor blockers, SRAR: steroid-resistant acute rejection) 
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6.4. Discussion 
Comparing the results of my own research and data found in literature we come to the 
conclusion that my research failed to confirm the hypotheses raised by other research 
groups. The strength of our results lies in the fact that our study is based on large 
number of cases as opposed to studies of small groups mentioned in the introduction.  
No other study has been published up to this point regarding transplant patients that 
deals with this topic in such depths.  
We can establish that receiving statin therapy in order to reduce cholesterol levels 
improves cardiovascular prevention in several ways, since the incidence of 
acetylsalicylic acid resistance is lower in this group. This is another component that can 
be added to the pleiotropic effects of statin therapy.   
Calcineurin inhibitor cyclosporine A has a number of serious side effects as well. Its 
nephrotoxic, hypertension and hyperlipidaemia inducing effects are well known so is its 
ability to increase cardiovascular mortality. According to the result of this study it also 
reduces the efficacy of ASA therapy.  
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7.  TREATMENT OPTIONS FOR PATIENTS WITH RESISTANCE  
 
7.1. Introduction 
In previous chapters the possible causes of resistance to aggregation inhibitors was 
described in detail furthermore why it is especially important to apply this type of 
therapy in populations having undergone transplantation. The treatment options for 
resistant patients have been examined by multiple studies. The overall conclusion is that 
in case of ASA resistance, according to most studies, conversion to clopidogrel appears 
to be a good choice or complementing ASA therapy with clopidogrel and if clopidogrel 
resistance occurs increasing doses or conversion to prasugrel is acceptable.  
7.2. Objectives 
My aim was to modify therapy of patients resistant to antiplatelet treatment relying on 
scientific literature, and to assess efficacy of the new therapy using aggregometric 
measurements.  
7.3. Patients and methods 
A follow-up study was carried out relying on groups of kidney and simultaneous 
pancreas-kidney transplant recipients earlier described in my thesis (Table 2). 
Out of the 123 patients, resistant to either ASA or clopidogrel, a total of 118 underwent 
control aggregometry. 96 of them instead of the 100 mg ASA therapy that proved to be 
ineffective got 75 mg clopidogrel a day, and 22 of them received 150 mg clopidogrel 
instead of the previous dose of 75 mg. 
Aggregometriy were performed as previously described. 
7.4. Results 
Conversion to ASA or clopidogrel brought the following results: in 41 patients 
(42.70%) aggregation inhibition was effective and in 55 patients (57.29%) the 
therapeutic change was ineffective (Diagram 1).  
Diagram 1: Results of conversion ASA-clopidogrel 
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Increased clopidogrel doses was effective in 9 patients (40.90%), but in 13 (59.09%) 
patients no proper aggregation inhibition could be detected, not even with a daily dose 
of 150 mg (Diagram 2).  
 
Diagram 2: The result of increased clopidogrel doses 
 
7.5. Discussion 
When deciding upon therapeutic changes of resistant patients we rely on data from 
literature and practical skills of the cardiology clinic performing aggregometric 
measurements.  The results show that conversion or increasing doses was only effective 
in approximately 40% of the cases. 
Comparing our ASA-clopidogrel conversion results with international data it is not 
surprising. Lev et al studied double-resistance of patient groups having had 
percutaneous coronary interventions and they found that 47.4% of the ASA resistant 
population was also resistant to clopidogrel. 
Clopidogrel resistance after the increase in doses was studied by Aleil et al as well. 
While with a dose of 75 mg the prevalence of resistance 33.7%, it dropped to 8.6% in 
the group receiving 150 mg a day (58 patients). Severe bleeding occurred in neither 
groups, and there were no significant discrepancies between two groups in terms of 
minor bleedings either. In summary, the changes made in resistant patients’ therapy did 
not always lead to efficient inhibition of aggregation. In sight of scientific literature it 
was not expected to happen. It is a positive result however that half of the patients that 
previously received ineffective therapy can have, through regular aggregometric check-
ups and on-time change in therapeutic drugs, effective platelet inhibition. 
The group still showing signs of resistance may benefit from switching to prasugrel or 
ticagrelor. 
Both agents have already been through a number of multi-centre trials that have proved 
their efficacy and lower rates of resistance. 
Due to current prescription rules we could not put our patients on the aforementioned 
therapy. 
 
 
9 
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8.  ASSESMENT OF CARDIOVASCULAR MORTALITY AND 
MORBIDITY AFTER TRANSPLANTATION  
 
8.1. Introduction 
Assessment of resistance to antiplatelet drugs and the consequent therapeutic 
modifications are implemented in order to decrease cardiovascular morbidity and 
mortality. We know what the most significant factors are that contribute to mortality in 
transplant patients, consequently we also know that cardiovascular prevention is 
essential in these patients. Prevention is also important because the number of implanted 
organs does not increase proportionally with the number of patients waiting for 
transplantation, thus protecting transplanted organs is extremely important. 
8.2. Objective 
The analysis morbidity and mortality rates of transplant patients and patients with a 
positive cardiovascular history. The comparison of cardiovascular mortality before and 
after our investigation, based on which we can determine the efficacy of necessary 
therapeutic modifications and regular aggregometric check-ups. Major cardiovascular 
events were summarised within the study period (stroke and acute myocardial 
infarction). 
8.3. Patients and methods 
The data of patients (286 simultaneous pancreas- kidney transplant recipients and renal 
transplant recipients) who underwent earlier aggregometric examinations were analysed 
based on documents from ambulatory care and the hospital computer system 
(MedSolution®). A gender and age suitable control group was selected from the 1st 
Department of Internal Medicine, University of Pecs with positive cardiovascular 
history (acute myocardial infarction, cerebrovascular events). The study period started 
in March 2009 and ended in December 2013. The comparison criteria were as follows: 
mortality, recent acute coronary syndrome (ACS) and the occurrence of stroke, 
hypertension, and diabetes. Using these criteria data of groups in Figure 1 were 
examined. The statistical analysis was with chi-square test using the 21.0 version IBM 
SPSS software (IBM Corporation, Armonk, New York, United States). 
 
 
 
 
 
Figure 1: Groups compared through statistical analysis 
8.4. Results 
Transplant recipients’ resistance to aggregation inhibitors is significantly higher than 
that of the control group (p <0.002). 
The incidence of acute coronary syndrome is also more common (P <0.03) in transplant 
patients. During a 16.5 year period before the start of our study out of the 586 
transplants patients 65 died due to cardiovascular causes. Between March 2009 and 
December 2013 in a span of 4.5 years out of 286 patients participating in our study 
Non-resistant recipients (NRT) 
Resistant recipients (RT) Resistant patients (RP) 
Non-resistant patients (NRP) 
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seven died due to the same causes. If we made a mathematical comparison between the 
two studies there would be a significant decrease in cardiovascular mortality. But 
because of the different timing of the studies and differences in terms of age, therapy 
and cardiovascular risk factors of patients they are not scientifically comparable.   
Most major cardiovascular events registered in clinical trials are stroke and acute 
myocardial infarction. 7 of our patients had stroke, and 11 AMI. 
The following tables summarize the results of the statistical analysis. 
 
cases / all 
recipients 
cases / all patients p significance 
Resistance 123/286 91/346 0,002 S 
Mortality 7/286 5/346 0,36 NS 
Recent ACS 11/286 4/346 0,03 S 
Recent stroke 7/286 7/346 0,72 NS 
Hypertension 270/286 240/346 0,009 S 
Diabetes 48/286 72/346 0,28 NS 
Table 9: Morbidity and mortality results of the analyzed population 
 
 
cases / RT cases / NRT  p significance 
Mortality 3/123 4/163 0,99 NS 
Recent ACS 8/123 3/163 0,05 S 
Recent stroke 6/123 1/163 0,02 S 
Hypertension 118/123 152/163 0,86 NS 
Diabetes 20/123 28/163 0,86 NS 
Table 10: Morbidity and mortality results of the transplanted patients regarding 
resistance 
 
 
cases / RP cases / NRP p significance 
Mortality 2/91 3/255 0,49 NS 
Recent ACS 2/91 2/255 0,28 NS 
Recent stroke 3/91 4/255 0,32 NS 
Hypertension 64/91 176/255 0,92 NS 
Diabetes 13/91 59/255 0,14 NS 
Table 11: Morbidity and mortality results of the positive control population regarding 
resistance 
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cases / RT  cases / RP  p significance 
Mortality 3/123 2/91 0,91 NS 
Recent ACS 8/123 2/91 0,15 NS 
Recent stroke 6/123 3/91 0,58 NS 
Hypertension 118/123 64/91 0,13 NS 
Diabetes 20/123 13/91 0,73 NS 
Table 12: Morbidity and mortality results of the resistant patients 
 
 
cases / NRT  cases / NRP  p significance 
Mortality 4/163 3/255 0,32 NS 
Recent ACS 3/163 2/255 0,33 NS 
Recent 
stroke 
1/163 4/255 0,38 NS 
Hypertension 152/163 176/255 0,04 S 
Diabetes 28/163 59/255 0,23 NS 
Table 13: Morbidity and mortality results of the non-resistant patients 
 
8.5. Discussion 
The transplantation has a dual purpose: on the one hand it substitutes a not functioning 
organ with a functioning one, and secondly it provides better graft survival in the long 
run. There are basically two possible outcomes of renal transplantation. The recipient 
either loses their functioning graft, or they die with it. In the latter case the leading 
causes of mortality are cardiovascular diseases, as in the normal population. Our 
primary aim is not to reduce this mortality rate, but to delay the time of its occurrence. 
The general trend is that the average age of those waiting for transplantation is getting 
higher year by year and also an increasing proportion of them have diabetes. A direct 
consequence of these factors is the increase in cardiovascular risk. It is important to 
maintain patients’ cardiovascular status that has lost their grafts, so that they remain 
candidates for transplantation.  
The comparison of the control and our patient groups confirms that cardiovascular 
diseases which are the leading cause of mortality in the general population are even 
more frequent in transplant recipients. The transplant group’s risks are further worsened 
by the increased resistance to platelet aggregation inhibitors that are even greater than 
that of a patient group at high cardiovascular risk.  
Based on the results we can see that for during the study period cardiovascular 
morbidity and mortality decreased compared to the period prior to our investigation. 
Therapeutic modification control of aggregation inhibition are not the only things that 
helped achieving this but also other conditions (e.g.: hypertension, hyperlipidaemia) 
recognised during ambulatory visits and background check and modify the therapeutic 
efficacy of the anti-aggregation treatment.  
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The result contributes to the treatment of other medical conditions detected during 
ambulatory care (e.g.: hypertension, hyperlipidaemia) as well. On top of this the study 
demonstrated the benefits of routine aggregometric measurements. 
It was shown in our patients that the incidence of acute coronary syndromes is more 
frequent in case of ASA resistance. 
The incidence of post-transplant acute myocardial infarction Lentine et al found that the 
incidence of myocardial infarction was 4.3% -5.6% -11.1%,   6-12-36 months after 
renal transplantation. 
Because of atherosclerosis caused by a period of uraemia before renal transplantation, 
the risk of stroke was also increased in these patients. This phenomenon was also 
observed in in our patient group. Selinger et al found that the risk of stroke in end stage 
renal failure is 5-10 times higher than in patients with normal kidney function. It is 
therefore not surprising that cerebrovascular events are leading causes of mortality even 
after transplantation. 
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9.  SUMMARY OF THE NEW SCIENTIFIC RESULTS  
 
1. It is the first time for a research of such large patient numbers to demonstrated that 
the incidence of resistance to platelet aggregation inhibitors in the transplanted 
population is significantly higher than in the average population. This factor can be 
looked at as a new cardiovascular risk factor. 
 
2. Our measurements have proven that the number of patients resistant to aggregation 
inhibitors can be decreased if we convert ASA-resistant patients from ASA to 
clopidogrel, or increase doses of clopidogrel in resistant patients. 
 
3. According to our measurements cyclosporine plays a role in acetylsalicylic acid 
resistance. Increased resistance is observed in our patients when they are used 
simultaneously. 
 
4. My study has demonstrated that statin therapy does not only reduce lipid levels, but it 
is also beneficial in reducing resistance. 
 
5. Based on these findings regular aggregometry can be suggested in the transplant 
population, so as to recognize resistance to aggregation inhibitors in time, and to be able 
to implement therapeutic changes accordingly. Consequently, the number of 
cardiovascular mortality and complications can be reduced or the time of their 
development delayed. 
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